@article{a31bfa6d92be4c30a6ea420376cb3ab4,
title = "Association between disease progression and depression onset in persons with radiographic knee osteoarthritis",
abstract = "Objectives. Osteoarthritis (OA) disease progression may lead to deteriorating psychosocial function, but it is unclear what aspects of disease severity are related to the onset of depression. This study assessed which components of OA disease progression cumulatively contribute to depression onset in persons with radiographic knee OA. Methods. Osteoarthritis Initiative participants (n ¼ 1651) with radiographic disease (Kellgren-Lawrence grade ≥2) in one or both knees and below the screening threshold for probable depression [Center for Epidemiological Studies Depression (CES-D) scale <16] at baseline were included. Disease severity was measured from baseline to the third annual follow-up visit using joint space width, 20-meter gait speed, and the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale, each categorized into quintiles. Depression onset (CES-D ≥ 16) was assessed annually at four follow-up visits. Marginal structural models that account for time-dependent confounding and attrition evaluated the association between each time-varying disease severity measure and depression onset. Results. Each disease severity measure exhibited a non-linear relationship concerning the probability of depression onset, with the higher quintiles generally being associated with a larger risk. The highest quintile (relative to the lowest) of joint space width and gait speed were both significantly associated with depression onset. By contrast, none of the higher pain quintiles compared with the lowest were significantly associated with the onset of depression. Conclusion. Faster disease progression as measured by either worsening structural severity or decreasing physical performance corresponds to an increased risk of depression among individuals with radiographic knee OA.",
keywords = "Depression, Epidemiology, Knee, Osteoarthritis, Quality of life",
author = "Rathbun, {Alan M.} and Shardell, {Michelle D.} and Ryan, {Alice S.} and Yau, {Michelle S.} and Gallo, {Joseph J.} and Schuler, {Megan S.} and Stuart, {Elizabeth A.} and Hochberg, {Marc C.}",
note = "Funding Information: All authors have actively participated in the work leading to this manuscript and have given approval for this version to be published. Individual authors have made the following contributions: A.M.R. conceptualized the study, performed the analyses, and wrote the manuscript; M.D.S., M.S.S. and E.A.S. assisted with analyses and contributed to the study design, interpretation of results and revisions to the manuscript; A.S.R., M.S.Y., J.J.G. and M.C.H. helped with study design and interpreting the results and critically reviewed and revised the manuscript. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public-use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH or the private funding partners. This paper is based on work that was presented previously at the 2018 EULAR Annual Meeting, 13 June 2018, Amsterdam and was published as a conference abstract: Rathbun et al. Ann Rheum Dis. 2018; 77 (suppl 2). Funding: This study was supported by the Rheumatology Research Foundation's Scientist Development Award and grants from the National Institute on Aging (K01 AG064041). Disclosure statement: A.M.R. is supported by grants from the Rheumatology Research Foundation and National Institute on Aging (NIA; K01 AG064041); M.D.S. is supported by grants from NIA (R01 AG048069); A.S.R. is supported by grants from the VA Rehabilitation Research and Development Service (I01 RX002790, I01 RX001461, I21 RX002870), NIA (P30 AG028747) and National Institute on Diabetes and Digestive and Kidney Disease (P30 DK072488); M.S.Y. is supported by grants from the National Institutes of Health (R01 AR075356); J.J.G. is supported by grants from the National Institute on Mental Health (NIMH; R25 MH104660); M.S.S. is an Associate Policy Researcher at RAND Corporation; E.A.S. is supported by grants from NIMH (R01 MH115487, P50 MH115842); M.C.H. is the President of Rheumcon Corporation and receives consulting fees from Bioiberica SA, Bristol-Myers Squibb, Eli Lilly, EMD Serono, Galapagos, IBSA Biotechniq SA, Novartis Pharma AG, Pfizer, Plexxikon, Samumed LLC, Theralogix LLC and TissueGene Inc. Publisher Copyright: {\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com",
year = "2020",
month = nov,
day = "1",
doi = "10.1093/rheumatology/keaa141",
language = "English (US)",
volume = "59",
pages = "3390--3399",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "11",
}